From epidemiological transition to modern cardiovascular epidemiology: hypertension in the 21st century

The Lancet

Volumn 388, Issue 10043, 2016, Pages 530-532

  Blacher, Jacques ^a   Levy, Bernard I ^b,c   Mourad, Jean Jacques ^d   Safar, Michel E ^a   Bakris, George ^e  

^a HÔTEL DIEU   (France)

^b HÔPITAL LARIBOISIÈRE   (France)

^c PARIS CARDIOVASCULAR RESEARCH CENTER   (France)

^d AVICENNE HOSPITAL   (France)

^e UNIVERSITY OF CHICAGO MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIHYPERTENSIVE AGENT;

ATRIAL FIBRILLATION; BLOOD PRESSURE MEASUREMENT; BLOOD PRESSURE REGULATION; CARDIOVASCULAR DISEASE; CARDIOVASCULAR MORTALITY; CARDIOVASCULAR RISK; CAUSE OF DEATH; CEREBROVASCULAR ACCIDENT; HEART FAILURE; HEART VENTRICLE WALL; HUMAN; HYPERTENSION; ISCHEMIC HEART DISEASE; LIFE EXPECTANCY; MORTALITY RATE; NOTE; PRIMARY PREVENTION; PRIORITY JOURNAL; SECONDARY PREVENTION; SYSTOLIC DYSFUNCTION; BLOOD PRESSURE; CARDIOVASCULAR DISEASES; COMBINATION DRUG THERAPY; COMPLICATION; DEMENTIA, VASCULAR; DRUG EFFECTS; HYPERTENSION, RENAL; NEPHRITIS; PATHOPHYSIOLOGY; STANDARDS;

ANTIHYPERTENSIVE AGENTS; ATRIAL FIBRILLATION; BLOOD PRESSURE; BLOOD PRESSURE DETERMINATION; CARDIOVASCULAR DISEASES; DEMENTIA, VASCULAR; DRUG THERAPY, COMBINATION; HEART FAILURE; HUMANS; HYPERTENSION; HYPERTENSION, RENAL; LIFE EXPECTANCY; NEPHRITIS;

EID: 84989162184     PISSN: 01406736     EISSN: 1474547X     Source Type: Journal    
DOI: 10.1016/S0140-6736(16)00002-7     Document Type: Note

References (20)

1. Omran, AR, The epidemiologic transition: a theory of the epidemiology of population change. 1971. Milbank Q 49 (2005), 509–538.
2. Omran, AR, The epidemiologic transition theory revisited thirty years later. World Health Stat Q 51 (1998), 99–119.
3. Ford, ES, Ajani, UA, Croft, JB, et al. Explaining the decrease in U.S. deaths from coronary disease, 1980–2000. N Engl J Med 356 (2007), 2388–2398.
4. Aouba, A, Eb, M, Rey, G, Pavillon, G, Jougla, E, Mortality data in France: the main causes of death in 2008 and trends since 2000. Bull Epidemiol Hebd 22 (2011), 249–255.
5. Zhang, Y, Protogerou, AD, Iaria, P, Safar, ME, Xu, Y, Blacher, J, Prognosis in the hospitalized very elderly: the PROTEGER study. Int J Cardiol 168 (2013), 2714–2719.
6. MF O'Rourke, Safar, ME, Dzau, V, The Cardiovascular Continuum extended: aging effects on the aorta and microvasculature. Vasc Med 15 (2010), 461–468.
7. Lewington, S, Clarke, R, Qizilbash, N, Peto, R, Collins, R, for the Prospective Studies Collaboration. Age-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studies. Lancet 360 (2002), 1903–1913.
8. Go, AS, Mozaffarian, D, Roger, VL, et al., for the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Heart disease and stroke statistics—2013 update: a report from the American Heart Association. Circulation 127 (2013), e6–245.
9. Benjamin, EJ, Levy, D, Vaziri, SM, RB D'Agostino, Belanger, AJ, Wolf, PA, Independent risk factors for atrial fibrillation in a population-based cohort The Framingham Heart Study. JAMA 271 (1994), 840–844.
10. Bakris, GL, Protecting renal function in the hypertensive patient: clinical guidelines. Am J Hypertens 18 (2005), 112S–119S.
11. Gąsecki, D, Kwarciany, M, Nyka, W, Narkiewicz, K, Hypertension, brain damage and cognitive decline. Curr Hypertens Rep 15 (2013), 547–558.
12. Blacher, J, Evans, A, Arveiler, D, et al., for the PRIME study group. Residual coronary risk in men aged 50–59 years treated for hypertension and hyperlipidaemia in the population: the PRIME study. J Hypertens 22 (2004), 415–423.
13. Verdecchia, P, Staessen, JA, Angeli, F, et al. Usual versus tight control of systolic blood pressure in non-diabetic patients with hypertension (Cardio-Sis): an open-label randomised trial. Lancet 374 (2009), 525–533.
14. Julius, S, Kjeldsen, SE, Weber, M, et al., for the VALUE trial group. Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the VALUE randomised trial. Lancet 363 (2004), 2022–2031.
15. Beckett, N, Peters, R, Tuomilehto, J, et al., for the HYVET study group. Immediate and late benefits of treating very elderly people with hypertension: results from active treatment extension to Hypertension in the Very Elderly randomised controlled trial. BMJ, 344, 2011, d7541.
16. Blacher, J, Staessen, JA, Girerd, X, et al. Pulse pressure not mean pressure determines cardiovascular risk in older hypertensive patients. Arch Intern Med 160 (2000), 1085–1089.
17. Verger, A, van der Gucht, A, Guedj, E, et al. Central pulse pressure is a determinant of heart and brain remodeling in the elderly: a quantitative MRI and PET pilot study. J Hypertens 33 (2015), 1378–1385.
18. Blacher, J, Halimi, JM, Hanon, O, et al., for the French Society of Hypertension. Management of hypertension in adults: the 2013 French Society of Hypertension guidelines. Fundam Clin Pharmacol 28 (2014), 1–9.
19. Marott, SC, Nielsen, SF, Benn, M, Nordestgaard, BG, Antihypertensive treatment and risk of atrial fibrillation: a nationwide study. Eur Heart J 35 (2014), 1205–1214.
20. Weidmann, P, De Myttenaere-Bursztein, S, Maxwell, MH, de Lima, J, Effect of aging on plasma renin and aldosterone in normal man. Kidney Int 8 (1975), 325–333.